C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2026)

C4 Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $61.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 19.46% year-over-year to $61.3 million; the TTM figure through Mar 2026 stood at $61.3 million (up 19.46% YoY), while the FY2025 annual figure was $74.6 million, up 34.42% from the prior year.
• Cash & Equivalents was $61.3 million for Q1 2026 at C4 Therapeutics, down from $74.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $126.6 million in Q4 2023 to a low of $29.8 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $62.7 million across 5 years, with a median of $58.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 79.62% in 2022, then surged 325.46% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $29.8 million in 2022, then soared by 325.46% to $126.6 million in 2023, then plunged by 56.16% to $55.5 million in 2024, then jumped by 34.42% to $74.6 million in 2025, then slipped by 17.87% to $61.3 million in 2026.
• The last three Cash & Equivalents figures came in at $61.3 million (Q1 2026), $74.6 million (Q4 2025), and $58.8 million (Q3 2025), per Business Quant data.